유리화 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 검체별(난자, 배, 정자), 최종 용도별, 지역별, 경쟁별(2020-2030년)

The Global Vitrification Market was valued at USD 9.53 billion in 2024 and is projected to reach USD 22.12 billion by 2030, registering a compound annual growth rate (CAGR) of 15.04% during the forecast period.

Vitrification, an advanced cryopreservation technique, has gained significant traction across multiple industries, ranging from medicine and biotechnology to environmental conservation. This process involves the transformation of a liquid into a solid glass-like state without crystallization. In cryopreservation, vitrification is particularly effective for preserving biological samples-such as cells, tissues, and embryos-at ultra-low temperatures (typically -196°C or -321°F). Unlike conventional freezing methods, vitrification eliminates the formation of ice crystals, thereby minimizing cellular damage and enhancing post-thaw viability.

The Assisted Reproductive Technology (ART) sector is a primary driver of market growth. Vitrification has revolutionized oocyte and embryo preservation, substantially improving success rates in in vitro fertilization (IVF) procedures. The technique also plays a vital role in stem cell banking and regenerative medicine, facilitating the long-term storage of pluripotent stem cells for use in advanced therapies and drug discovery. Additionally, vitrification is increasingly adopted in biobanking, where it enables the secure, long-term storage of biological specimens critical for clinical research.

Emerging applications include organ preservation, where vitrification holds the potential to extend the viability of donor organs and enhance transplant outcomes. Moreover, in environmental conservation, the technology is being utilized to preserve genetic material from endangered species and to safeguard plant biodiversity through seed cryopreservation.

Key Market Drivers

Growth in Biobanking and Tissue Engineering

The rapid expansion of biobanking and tissue engineering has become a major catalyst for the global vitrification market. Vitrification's ability to preserve biological specimens in a glass-like state at ultra-low temperatures is essential for ensuring the long-term integrity of samples used in both research and clinical settings.

Biobanks, which store a wide range of biological materials-such as DNA, tissues, and cells-play a crucial role in medical research and therapeutic development. According to the World Health Organization (WHO), over 120 biobanks globally held more than 20 million biological samples as of 2023. The increasing demand for reliable preservation methods has positioned vitrification as a preferred technique due to its superior ability to maintain cellular structure and viability over extended periods.

Key Market Challenges

High Cost of Vitrification Technology

Despite its advantages, the high cost associated with vitrification technology presents a significant barrier to market expansion. The process requires advanced equipment, specialized cryoprotectants, and highly skilled personnel, all of which contribute to elevated capital and operational expenditures.

Establishing a vitrification facility necessitates investment in programmable freezers, cryogenic storage systems, and other high-grade materials. Additionally, continuous maintenance-including liquid nitrogen supply, regulatory compliance, and equipment calibration-further inflates operational costs.

Labor costs are also considerable, as embryologists and laboratory technicians must undergo extensive training to handle sensitive biological materials with precision. Any deviation from protocol can compromise the viability of preserved samples, emphasizing the need for highly qualified professionals.

In developing countries or regions with constrained healthcare budgets, the cost of implementing vitrification technologies can be prohibitive. This limits geographic expansion and restricts access to fertility preservation services for lower-income populations-particularly patients undergoing cancer treatment or gender-affirming care.

Moreover, insurance coverage for fertility preservation is often limited or unavailable, placing the financial burden on patients. The high out-of-pocket expenses discourage many from pursuing vitrification, especially when multiple treatment cycles are required. These economic limitations hinder the widespread adoption of vitrification technologies and raise broader concerns about equitable access to advanced reproductive healthcare.

Key Market Trends

Advancements in Technology

Technological innovation continues to reshape the vitrification landscape, particularly in cryopreservation. Traditional freezing methods often resulted in ice crystal formation, leading to cellular damage. New vitrification techniques eliminate this risk, enabling safer and more effective preservation of cells, tissues, and even entire organs. This progress has significant implications for organ transplantation, IVF, and stem cell therapies.

In materials science, the development of enhanced glass-forming substances with improved resistance to thermal shock and greater transparency is facilitating broader application of vitrification in optics, where precision components such as lenses and prisms require high-quality materials.

The pharmaceutical and biotechnology sectors are also embracing vitrification to develop stable and long-lasting formulations for biopharmaceuticals and vaccines. These methods ensure the preservation of drug efficacy during storage and transport-particularly valuable in resource-limited settings.

In the electronics industry, vitrification is being applied to the production of high-performance devices. Technologies like amorphous silicon and other vitrified materials are central to the manufacture of thin-film transistors and liquid crystal displays (LCDs), contributing to more efficient, lightweight, and visually superior electronic products.

These diverse advancements are expanding the scope of vitrification well beyond traditional biological preservation, positioning it as a transformative technology across multiple high-growth industries.

Key Market Players

• Vitrolife Inc.
• Genea Biomedx inc.
• NidaCon International AB
• Minitube International
• IMV Technologies Group (Cryo Bio System)
• The Cooper Companies, Inc. (A CooperSurgical Fertility Company)
• FUJIFILM Corporation (FUJIFILM Irvine Scientific)
• Biotech, Inc.
• Kitazato Corporation
• Shenzhen VitaVitro BiotechAGEN N.V.

Report Scope:

In this report, the Global Vitrification Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Vitrification Market, By Specimen:

• Oocytes
• Embryo
• Sperm

Vitrification Market, By End-use:

• IVF Clinics
• Biobanks

Vitrification Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Vitrification Market.

Available Customizations:

Global Vitrification market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

4. Voice of Customer

5. Global Vitrification Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Specimen (Oocytes (Devices, Kits & Consumables) ,Embryo (Devices, Kits & Consumables), Sperm)
  • 5.2.2. By End-use (IVF Clinics, Biobanks)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Vitrification Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Specimen
  • 6.2.2. By End-use
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Vitrification Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Specimen
      • 6.3.1.2.2. By End-use
  • 6.3.2. Canada Vitrification Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Specimen
      • 6.3.2.2.2. By End-use
  • 6.3.3. Mexico Vitrification Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Specimen
      • 6.3.3.2.2. By End-use

7. Europe Vitrification Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Specimen
  • 7.2.2. By End-use
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Vitrification Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Specimen
      • 7.3.1.2.2. By End-use
  • 7.3.2. United Kingdom Vitrification Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Specimen
  • 7.3.3. Italy Vitrification Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Specimen
      • 7.3.3.2.2. By End-use
  • 7.3.4. France Vitrification Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Specimen
      • 7.3.4.2.2. By End-use
  • 7.3.5. Spain Vitrification Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Specimen
      • 7.3.5.2.2. By End-use

8. Asia-Pacific Vitrification Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Specimen
  • 8.2.2. By End-use
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Vitrification Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Specimen
      • 8.3.1.2.2. By End-use
  • 8.3.2. India Vitrification Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Specimen
      • 8.3.2.2.2. By End-use
  • 8.3.3. Japan Vitrification Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Specimen
      • 8.3.3.2.2. By End-use
  • 8.3.4. South Korea Vitrification Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Specimen
      • 8.3.4.2.2. By End-use
  • 8.3.5. Australia Vitrification Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Specimen
      • 8.3.5.2.2. By End-use

9. South America Vitrification Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Specimen
  • 9.2.2. By End-use
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Vitrification Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Specimen
      • 9.3.1.2.2. By End-use
  • 9.3.2. Argentina Vitrification Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Specimen
      • 9.3.2.2.2. By End-use
  • 9.3.3. Colombia Vitrification Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Specimen
      • 9.3.3.2.2. By End-use

10. Middle East and Africa Vitrification Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Specimen
  • 10.2.2. By End-use
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Vitrification Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Specimen
      • 10.3.1.2.2. By End-use
  • 10.3.2. Saudi Arabia Vitrification Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Specimen
      • 10.3.2.2.2. By End-use
  • 10.3.3. UAE Vitrification Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Specimen
      • 10.3.3.2.2. By End-use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition
• 12.2. Product Development
• 12.3. Recent Developments

13. Global Vitrification Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Vitrolife Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Genea Biomedx inc.
• 14.3. NidaCon International AB
• 14.4. Minitube International
• 14.5. IMV Technologies Group (Cryo Bio System)
• 14.6. The Cooper Companies, Inc. (A CooperSurgical Fertility Company)
• 14.7. FUJIFILM Corporation (FUJIFILM Irvine Scientific)
• 14.8. Biotech, Inc.
• 14.9. Kitazato Corporation
• 14.10. Shenzhen VitaVitro BiotechAGEN N.V.

15. Strategic Recommendations

16. About Us & Disclaimer